Design and Development of Taste Masked Formulations of Model Drug by Using Eudragit L-100: A Recent Study

Tenofovir disoproxil fumarate is a nucleotide reverse transcriptase inhibitor medication with a very bitter taste that plays an essential role in patient compliance in the oral dosing form. In this study, an attempt was made to mask the bitter taste of Tenofovir Disproxil Fumarate utilising a complexation process and an oral dispersible tablet formulation including super disintegrant croscarmellose sodium in various concentrations. Polymer Eudragit L -100 was used in the formulation of the complex with the Tenofovir Disproxil Fumarate. The complexes were formulated as 1:1, 1:2 and 1:3 ratios. The drug and polymer ratio were used to optimise the loading procedure. Taste masking was determined using the panel method, and the complexes were characterised using FTIR. Oral dispersible tablets were manufactured and assessed for pre-formulation and post-formulation parameters using the optimised drug-polymer complexes (1:3 ratio). The formulations were tested for thickness, hardness, diameter, weight variation, friability, disintegration time, invitro dissolution time, and stability. The test is passed by all parameters. This discovery can be used to develop a non-bitter Tenofovir Disoproxil Fumarate dosage form with high bioavailability and stability.